Instructions for Notrocetam (Piracetam) 200 mg 10 ampoules
Notrocetam (Piracetam) 200 mg 10 ampoules
English product name
Notrocetam
Release form
Solution for in/in and in/m introduction
Description
The solution for in/in and in/m injection is colorless or with a slightly yellowish tint, transparent.
1 ml
piracetam 200 mg
Auxiliary substances: sodium trihydrate acetate (sodium acetic acid 3-aqueous), acetic acid diluted 30%, water d/i.
5 ml - neutral glass ampoules (5) - contoured box packaging (1) - cardboard packages.
5 ml - neutral glass ampoules (5) - contoured box packaging (2) - cardboard packages.
ATC codes
N06BX03 Piracetam
Clinical-pharmacological groups / Group affiliation
Nootropic preparation
Active substance
piracetam
Pharmacotherapy group:
Nootropic agent
Pharmacological effect Piracetam:
Nootropic agent. It has a positive effect on metabolic processes and brain circulation. Improves glucose utilization, improves metabolic processes, improves microcirculation in ischemized areas, inhibits aggregation of activated platelets. It has a protective effect for brain damage caused by hypoxia, intoxication, electroshock. Improves the integrative activity of the brain. It has no sedative and psychostimulative effects. Reduces the duration of the induced vestibular neuronite. Inhibits the increased aggregation of activated platelets and, in the case of pathological erythrocyte rigidity, improves their deformability and filtration ability.
Testimony Piracetam:
Memory impairments, dizziness, decreased concentration, emotional lability, dementia due to disorders of cerebral circulation (ischemic stroke), brain injuries, Alzheimer's disease, in old age; comatose states of vascular, traumatic or toxic genesis; treatment of withdrawal and psychoorganic syndrome in chronic alcoholism; Learning disabilities in children not related to inadequate learning or family environment (as part of combination therapy); sickle cell disease (as part of combination therapy).
Method of use, course and dosage:
Used inwards, in/m or in/w. The dose, method and procedure for the use and duration of therapy are determined individually, depending on the indications, clinical situation, patient age and the dosage form used.
The parenteral administration of piracetam is prescribed when the oral forms (unconscious state, difficulty swallowing) cannot be applied. The preferred method is to introduce.
- Nosology (ICD codes)
- D57
- Sickle cell disorders
- F00
- Dementia in Alzheimer's disease
- F01
- Vascular dementia
- F03
- Dementia unspecified
- F07
- Personality and behavioural disorders caused by disease, damage or brain dysfunction
- F10.2
- Chronic alcoholism
- F10.3
- Withdrawal state
- F81
- Specific learning disabilities
- G45
- Transitory cerebral ischemic attacks [attacks] and related syndromes
- I63
- Brain infarction
- I69
- Effects of cerebrovascular disease
- R42
- Dizziness and disturbance of stability
- T90
- Effects of head injuries
